Stay updated on FT538 with Daratumumab in AML Clinical Trial
Sign up to get notified when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.

Latest updates to the FT538 with Daratumumab in AML Clinical Trial page
- Check4 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure and Revision: v3.3.2 links were removed.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedAdded Revision: v3.3.2 to the record history and removed Revision: v3.2.0. This is an administrative update to the page's versioning and does not alter study data or page content.SummaryDifference0.1%

- Check39 days agoChange DetectedDeleted a government funding notice about site operations. The core study history information remains unaffected.SummaryDifference0.7%

- Check54 days agoChange DetectedNew versions in the record history show updates to Study Status and Recruitment Status. The changes reflect the trial’s evolving state and its enrollment status.SummaryDifference0.2%

- Check82 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference12%

- Check90 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.3%

Stay in the know with updates to FT538 with Daratumumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.